Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting

References

• Lindkvist B, De Valle MB, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–577.
   PubMed Web of Science ®Google Scholar
• Card T, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–944.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Weersma RK, vanErpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–2055.
   PubMed Web of Science ®Google Scholar
• Olsson R, Danielsson A, Järnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319–1323.
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastoenterol. 1997;32:604–610.
   PubMed Web of Science ®Google Scholar
• Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151:660–669.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–1599.
   PubMed Web of Science ®Google Scholar
• Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–615.
   PubMed Web of Science ®Google Scholar
• Liu K, Wang R, Kariyawasam V, et al. Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. Liver Int. 2017;37:442–448.
   PubMed Web of Science ®Google Scholar
• Ngu JH, Gearry RB, Wright AJ, et al. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:1092–1097.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–96.
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–327.
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Hecker H, Krüger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107–114.
   PubMed Web of Science ®Google Scholar
• Poropat G, Giljaca V, Stimac D, et al. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011;CD003626. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12804480.
   Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–814.
   PubMed Web of Science ®Google Scholar
• Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–67.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37:604–612.
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30:1121–1127.
   PubMed Web of Science ®Google Scholar
• Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc. 2003;35:2431–2434.
   PubMed Web of Science ®Google Scholar
• Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854–862.
   PubMed Web of Science ®Google Scholar
• Oshitani N, Jinno Y, Sawa Y, et al. Does colitis associated with primary sclerosing cholangitis represent an actual subset of ulcerative colitis? Hepatogastroenterology. 2003;50:1830–1835.
   PubMedGoogle Scholar
• Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18:154–161.
   PubMed Web of Science ®Google Scholar
• Moayyeri A, Daryani NE, Bahrami H, et al. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol. 2005;20:366–370.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Grzyb K, Lundin KE, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012;18:536–545.
   PubMed Web of Science ®Google Scholar
• Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997;40:451–456.
   PubMed Web of Science ®Google Scholar
• Broomé U, Löfberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:1301–1305.
   PubMed Web of Science ®Google Scholar
• Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224–1228.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Venkatesh PG, Mukewar S, et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:540–546.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Boberg KM, Vatn M, et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun. 2007;8:275–278.
   PubMed Web of Science ®Google Scholar
• Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681–1689.
   PubMed Web of Science ®Google Scholar
• Wiesner RJ, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10:430–436.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Venkatesh PGK, Lashner BA, et al. The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2012;35:1045–1053.
   PubMed Web of Science ®Google Scholar
• Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: a population-based study. Scand J Gastroenterol. 1997;32:1042–1045.
   PubMed Web of Science ®Google Scholar
• Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790–794.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:563–575.
   PubMed Web of Science ®Google Scholar
• Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688–694.
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology. 1999;29:1643–1648.
   PubMed Web of Science ®Google Scholar
• Abu-Elmagd KM, Malinchoc M, Dickson ER, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet. 1993;177:335–344.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–485.
   PubMed Web of Science ®Google Scholar
• Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–1165.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, French B, Thomasson A, et al. Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation. 2011;91:1148–1152.
   PubMed Web of Science ®Google Scholar
• Goldberg D, French B, Thomasson A, et al. Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl. 2011;17:1355–1363.
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network. Guidance on MELD PELD exception review [Internet]. Washington, DC: U.S. Department of Health & Human Services; 2015 cited 2017 February 24. Available from: https://optn.transplant.hrsa.gov/resources/by-organ/liver-intestine/guidance-on-meld-peld-exception-review/
   Google Scholar
• Freeman RB Jr, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006;12:S126–S136.
   Web of Science ®Google Scholar
• Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526.
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Isoniemi H, Broomé U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004;40:815–822.
   PubMed Web of Science ®Google Scholar
• Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl. 2005;11:1412–1416.
   PubMed Web of Science ®Google Scholar
• Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633–1637.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–207.
   PubMed Web of Science ®Google Scholar
• Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol. 2016;185:61–71.
   PubMed Web of Science ®Google Scholar
• Voigtländer T, David S, Thamm K, et al. Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma. PLoS One. 2014;9:e97046.
   PubMed Web of Science ®Google Scholar
• Lewis JT, Talwalkar JA, Rosen CB, et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007;31:907–913.
   PubMed Web of Science ®Google Scholar
• Joshi D, Bjarnason I, Belgaumkar A, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int. 2013;33:53–61.
   PubMed Web of Science ®Google Scholar
• Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422–1429.
   PubMed Web of Science ®Google Scholar
• Eaden J, Abrams K, Mayberry J. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.
   PubMed Web of Science ®Google Scholar
• Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.
   PubMed Web of Science ®Google Scholar
• Lewin MR, Clark CG. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet. 1987;2:973–974.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer. 1977;39:2533–2539.
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95.
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–893.
   PubMed Web of Science ®Google Scholar
• Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22:783–788.
   PubMed Web of Science ®Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–1353.
   PubMed Web of Science ®Google Scholar
• Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367–371.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731–736.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Lindström L, Cvancarova M, et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastoenterol. 2012;47:1021–1029.
   PubMed Web of Science ®Google Scholar
• Montomoli J, Erichsen R, Christiansen CF, et al. Liver disease and 30-day mortality after colorectal cancer surgery: a Danish population-based cohort study. BMC Gastroenterol. 2013;13:66.
   PubMed Web of Science ®Google Scholar
• Post AB, Bozdech JM, Lavery I, et al. Colectomy in patients with inflammatory bowel disease and primary sclerosing cholangitis. Dis Colon Rectum. 1994;37:175–178.
   PubMed Web of Science ®Google Scholar
• Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75:1983–1988.
   PubMed Web of Science ®Google Scholar
• Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis Colon Rectum. 2003;46:173–178.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Dasika NL, Yu E, et al. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery. J Clin Gastroenterol. 2009;43:574–579.
   PubMed Web of Science ®Google Scholar
• Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission. Nutrition. 2008;24:694–702.
   PubMed Web of Science ®Google Scholar
• Henkel AS, Buchman AL. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2006;3:202–209.
   PubMedGoogle Scholar
• Langer G, Großmann K, Fleischer S, et al. Nutritional interventions for liver-transplanted patients. Cochrane Database Syst Rev. 2012;8:CD007605.
   Google Scholar
• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
   PubMed Web of Science ®Google Scholar
• Neuberger J, Gunson B, Komolmit P, et al. Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology. 1999;29:1375–1379.
   PubMed Web of Science ®Google Scholar
• Steib A, Freys G, Lehmann C, et al. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth. 2001;48:1075–1079.
   PubMed Web of Science ®Google Scholar
• Chen P, Wang W, Yan L, et al. Risk factors for first-year hospital readmission after liver transplantation. Eur J Gastroenterol Hepatol. 2015;27:600–606.
   PubMed Web of Science ®Google Scholar
• Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–2546.
   PubMed Web of Science ®Google Scholar
• Nair S, Vanatta JM, Arteh J, et al. Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. Liver Transpl. 2009;15:1519–1524.
   PubMed Web of Science ®Google Scholar
• Wiesner RH, LaRusso NF, Dozois RR, et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology. 1986;90:316–322.
   PubMed Web of Science ®Google Scholar
• Kartheuser AH, Dozois RR, LaRusso NF, et al. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc. 1996;71:748–756.
   PubMed Web of Science ®Google Scholar
• Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–239.
   PubMed Web of Science ®Google Scholar
• Welsh FK, Wigmore SJ. Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation. 2004;77:602–604.
   PubMed Web of Science ®Google Scholar
• Pandanaboyana S, Bell R, Bartlett AJ, et al. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int. 2015;28:485–491.
   PubMed Web of Science ®Google Scholar
• Said A, Safdar N, Lucey MR, et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant. 2004;4:574–582.
   PubMed Web of Science ®Google Scholar
• Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 1991;126:149–156.
   PubMedGoogle Scholar
• Kashyap R, Safadjou S, Chen R, et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases–an analysis of the UNOS database. J Gastrointest Surg. 2010;14:1362–1369.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, French B, Abt PL, et al. Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology. 2014;60:1717–1726.
   PubMed Web of Science ®Google Scholar
• Graziadei IW. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr Opin Gastroenterol. 2011;27:301–305.
   PubMed Web of Science ®Google Scholar
• Gordon FD, Goldberg DS, Goodrich NP, et al. Recurrent primary sclerosing cholangitis in the adult-to-adult living donor liver transplantation cohort study: comparison of risk factors between living and deceased donor recipients. Liver Transpl. 2016;22:1214–1222.
   PubMed Web of Science ®Google Scholar
• Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl. 2006;12:S15–9.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Klöters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–156.
   PubMed Web of Science ®Google Scholar
• Gluck M, Cantone NR, Brandabur JJ, et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032–1039.
   PubMed Web of Science ®Google Scholar
• Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308–312.
   PubMed Web of Science ®Google Scholar
• Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108:1417–1425.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Lindström L, Cvancarova M, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:517–523.
   PubMed Web of Science ®Google Scholar
• Haagsma EB, van den Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther. 2003;18:33–44.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut. 1998;43:639–644.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Choudhary M, Venkatesh PGK, et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2012;35:1054–1063.
   PubMed Web of Science ®Google Scholar
• Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35:380–384.
   PubMed Web of Science ®Google Scholar
• Verdonk RC, Haagsma EB, van den Berg AP, et al. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection. Scand J Gastoenterol. 2006;41:205–211.
   PubMed Web of Science ®Google Scholar
• Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998;65:393–396.
   PubMed Web of Science ®Google Scholar
• Mohabbat AB, Sandborn WJ, Loftus EV Jr, et al. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012;36:569–574.
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, D’Alessandro AM, Harms BA, et al. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery. 1995;118:615–620.
   PubMed Web of Science ®Google Scholar
• Rowley S, Candinas D, Mayer AD, et al. Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation. Gut. 1995;37:845–847.
   PubMed Web of Science ®Google Scholar
• Riley TR, Schoen RE, Lee RG, et al. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279–282.
   PubMed Web of Science ®Google Scholar
• Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl. 2005;11:881–890.
   PubMed Web of Science ®Google Scholar
• Barritt AS, Zacks SL, Rubinas TC, et al. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature. Inflamm Bowel Dis. 2008;14:1695–1700.
   PubMed Web of Science ®Google Scholar
• Pavlidis P, Heneghan M, Hayee B. Cholestyramine treats primary sclerosing cholangitis-associated inflammatory bowel disease. J Crohns Colitis. 2015;9:210.
   PubMed Web of Science ®Google Scholar
• Lim TY, Pavlidis P, Gulati S, et al. Vedolizumab in inflammatory bowel disease associated with autoimmune liver disease pre- and postliver transplantation: a case series. Inflamm Bowel Dis. 2016;22:E39–40.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Vedolizumab joint GIDAC and DSaRM meeting [Internet]. 2013 [cited 2017 February 25]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM378753.pdf.
   Google Scholar
• Loftus EV Jr, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998;27:685–690.
   PubMed Web of Science ®Google Scholar
• Watt KD, Pedersen RA, Kremers WK, et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137:2010–2017.
   PubMed Web of Science ®Google Scholar
• Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2009;15:1331–1336.
   PubMed Web of Science ®Google Scholar
• Hanouneh IA, Macaron C, Lopez R, et al. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2012;18:269–274.
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Belle SH, Beringer KC, et al. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. Clin Transpl. 1998;17–37. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10503083.
   PubMedGoogle Scholar
• Brandsaeter B, Friman S, Broomé U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastoenterol. 2003;38:1176–1183.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004;99:538–542.
   PubMed Web of Science ®Google Scholar
• Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis: a 12-year single center experience. Ann Surg. 1997;225:472–481.
   PubMed Web of Science ®Google Scholar
• Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18:1–15.
   PubMed Web of Science ®Google Scholar
• Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15:330–340.
   PubMed Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14:181–185.
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29:1050–1056.
   PubMed Web of Science ®Google Scholar
• Ravikumar R, Tsochatzis E, Jose S, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63:1139–1146.
   PubMed Web of Science ®Google Scholar
• Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–1824.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138–143.
   PubMed Web of Science ®Google Scholar
• Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation. 1998;66:1300–1306.
   PubMed Web of Science ®Google Scholar
• Alexander J, Lord JD, Yeh MM, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:245–251.
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl. 2005;11:1361–1369.
   PubMed Web of Science ®Google Scholar
• Heneghan MA, Tuttle-Newhall JE, Suhocki PV, et al. De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am J Transplant. 2003;3:634–638.
   PubMed Web of Science ®Google Scholar
• Landaverde C, Ng V, Sato A, et al. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol. 2009;8:379–383.
   PubMed Web of Science ®Google Scholar
• Sridhar AR, Parasa S, Navaneethan U, et al. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2011;5:287–294.
   PubMed Web of Science ®Google Scholar
• Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol. 1997;26:554–559.
   PubMed Web of Science ®Google Scholar
• Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000;69:1873–1881.
   PubMed Web of Science ®Google Scholar
• Narumi S, Roberts JP, Emond JC, et al. Liver transplantation for sclerosing cholangitis. Hepatology. 1995;22:451–457.
   PubMed Web of Science ®Google Scholar
• Miki C, Harrison JD, Gunson BK, et al. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg. 1995;82:1114–1117.
   PubMed Web of Science ®Google Scholar
• Sheng R, Zajko AB, Campbell WL, et al. Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases. AJR Am J Roentgenol. 1993;161:297–300.
   PubMed Web of Science ®Google Scholar
• Seehofer D, Eurich D, Veltzke-Schlieker W, et al. Biliary complications after liver transplantation: old problems and new challenges. Am J Transplant. 2013;13:253–265.
   PubMed Web of Science ®Google Scholar
• Liu K, Joshi V, Saxena P, et al. Predictors of success for double balloon-assisted endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anastomosis. Dig Endosc. 2017;29:190–197.
   PubMed Web of Science ®Google Scholar